GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharmaresearch Bio Co Ltd (XKRX:217950) » Definitions » EBITDA Margin %

Pharmaresearch Bio Co (XKRX:217950) EBITDA Margin % : 41.89% (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Pharmaresearch Bio Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pharmaresearch Bio Co's EBITDA for the six months ended in Dec. 2023 was ₩8,391 Mil. Pharmaresearch Bio Co's Revenue for the six months ended in Dec. 2023 was ₩20,031 Mil. Therefore, Pharmaresearch Bio Co's EBITDA margin for the quarter that ended in Dec. 2023 was 41.89%.


Pharmaresearch Bio Co EBITDA Margin % Historical Data

The historical data trend for Pharmaresearch Bio Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmaresearch Bio Co EBITDA Margin % Chart

Pharmaresearch Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial 3.23 18.15 33.77 61.21 41.89

Pharmaresearch Bio Co Semi-Annual Data
Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin % Get a 7-Day Free Trial 3.23 18.15 33.77 61.21 41.89

Competitive Comparison of Pharmaresearch Bio Co's EBITDA Margin %

For the Biotechnology subindustry, Pharmaresearch Bio Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmaresearch Bio Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmaresearch Bio Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Pharmaresearch Bio Co's EBITDA Margin % falls into.



Pharmaresearch Bio Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Pharmaresearch Bio Co's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=8391.091/20030.641
=41.89 %

Pharmaresearch Bio Co's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=8391.091/20030.641
=41.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pharmaresearch Bio Co  (XKRX:217950) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Pharmaresearch Bio Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Pharmaresearch Bio Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharmaresearch Bio Co (XKRX:217950) Business Description

Traded in Other Exchanges
N/A
Address
641-3, Saimdang-ro, Gangwon-do, Gangneung-si, KOR, 13494
Pharmaresearch Bio Co Ltd is a Korea-based biopharmaceutical company. The company is engaged in the research and development, manufacturing, sale, and marketing of biopharmaceutical products. Its product is ReNTox Injections, and Clostridium Botulinum Toxin type A is in pipeline.

Pharmaresearch Bio Co (XKRX:217950) Headlines

No Headlines